Résumé
Le congrès TAT (targeted anticancer therapies) est dédié aux essais précoces et aux molécules innovantes en cours de développement. La session 2016 a permis d’apercevoir le futur de l’immunothérapie antitumorale et des thérapies ciblées. Agir sur l’immunité antitumorale implique de relever de nombreux défis : mieux sélectionner les patients, comprendre les interactions avec le microbiome, développer des approches combinées et des traitements par lymphocytes autologues modifiés. Les développements des thérapies ciblées sont également porteurs de nombreuses promesses, grâce à la généralisation du profilage moléculaire des tumeurs et à de nombreuses avancées dans le traitement des cancers porteurs d’altérations du métabolisme, du cycle cellulaire ou des mécanismes de réparation de l’ADN. De nouvelles stratégies thérapeutiques permettent également de commencer à cibler KRAS ou p53. Enfin, la prise en charge des métastases cérébrales nécessite de proposer des approches innovantes.
Abstract
Targeted anticancer therapies congress is dedicated to new drugs in early development. The 2016 session was held in Washington, DC, and took a glimpse on the future of immunotherapy and targeted molecular therapies. The activation of antitumor immunity involves numerous challenges, such as better patient selection, deeper understanding of interactions with gut microbiota, and breakthrough expertise for the engineering of chimeric antigen receptor T-cells. Development of targeted molecular therapies is promising as well, with high-throughput sequencing available in clinical practice for better patient stratification, new agents for the treatment of cell cycle, metabolism, and DNA repair alterations, as well as difficult targets and localizations. Such improvements will soon be available in clinical routine and will undoubtedly improve the management of patients in the near future.
This is a preview of subscription content, log in via an institution to check access.
Références
Rosenberg S (2016) Curative potential of T-cell immunotherapy for cancer. Presented at TAT congress 2016. Front Oncol. Doi:10.3389/978-2-88919-879-5
O’Sullivan CC, Moon DH, Kohn EC and Lee JM (2014) Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol 4:42. Doi: 10.3389/fonc.2014.00042
Brown JR, Byrd JC, Coutre SE, et al (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood 123(22):3390–7
Furman RR, Sharman JP, Coutre SE, et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997–1007
Byrd JC, Furman RR, Coutre SE, et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42
Byrd JC, Brown JR, O’Brien S, et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213–23
Burger JA, Tedeschi A, Barr PM, et al (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 373:2425–37
Burger JA, Keating MJ, Wierda WG, et al (2014) Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15:1090–9
Chanan-Khan A, Cramer P, Demirkan F, et al (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Onco 17:200–11
Porter DL, Hwang WT, Frey NV, et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.Sci Transl Med 7 (303):303ra139
Swanton C (2016) Clinical implications of intratumour heterogeneity. Presented at TAT congress 2016. Front Oncol. Doi:10.3389/978-2-88919-879-5
Winkler J (2016) PROTAC BRD4 degraders allow a more effective therapeutic strategy than BRD4 inhibitors. Presented at TAT congress 2016. http://tatcongress.org/wp-content/uploads/2016/03/O11.4-James-Winkler.pdf
Hidalgo M (2016) Integrating PDX models in personalized medicine strategies. Presented at TAT congress 2016. Front Oncol. Doi:10.3389/978-2-88919-879-5
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Flippot, R., Bouallagui, I., du Rusquec, P. et al. Les actualités marquantes du congrès Targeted Anticancer Therapies — TAT 2016. Oncologie 18, 451–462 (2016). https://doi.org/10.1007/s10269-016-2651-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-016-2651-3